# Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients With MoCD Type A Currently Treated With rcPMP

> **NCT02047461** · PHASE2 · COMPLETED · sponsor: **Origin Biosciences** · enrollment: 8 (actual)

## Conditions studied

- Molybdenum Cofactor Deficiency, Type A

## Interventions

- **DRUG:** ORGN001 (formerly ALXN1101)

## Key facts

- **NCT ID:** NCT02047461
- **Lead sponsor:** Origin Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2022-08
- **Final completion:** 2022-10
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2023-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02047461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02047461, "Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients With MoCD Type A Currently Treated With rcPMP". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02047461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*